An early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
List view / Grid view
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
Safety updates to labels of SGLT2 inhibitors will recommend temporary discontinuation of these medications before scheduled surgery, says the FDA.
More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research finds...
25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…